Is Intellia a Good Gene-Editing Stock to Buy Now?
3/3 12:29
The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NASDAQ: NTLA) dazzled the medical community with clinical trial results for its lead candidate, the fight for intellectual property rights related...